Use of interferon gamma following prrimary graft failure after hematopoietic stem cell transplantation in a patient with chronic granulomatous disease in a public hospital in Peru: a case report
DOI:
https://doi.org/10.24265/horizmed.2025.v25n2.11Keywords:
Interferon Type I , Granulomatous Disease, Chronic , Bone Marrow TransplantationAbstract
We present the case of a male patient aged one year and six months, diagnosed with chronic
granulomatous disease since the first month of life, due to a mutation in the CYBB gene. Early
diagnosis was possible due to a family history of the same disease in an older brother aged 11
years and the detection of the mutation in the mother (carrier). The patient had a history of two
hospitalizations. The first lasted five months and was due to a diagnosis of community-acquired
pneumonia, complicated by respiratory failure, acute infectious diarrhea due to Pseudomonas
aeruginosa and cytomegalovirus infection. The second hospitalization occurred at 11 months of
age due to sepsis of gastrointestinal and respiratory origin.
The patient received antimicrobial prophylaxis with trimethoprim-sulfamethoxazole, itraconazole
and acyclovir, along with monthly intravenous immunoglobulin infusions, with limited response.
During the first hospitalization, at five months of age, a hematopoietic stem cell transplant was
attempted using his father as the donor; however, 0 % chimerism was achieved. Since October 2024 (at 12 months of age), subcutaneous interferon gamma therapy was initiated—representing the first reported case of its use in
Peru. Currently, six months after the initiation of interferon gamma therapy, the patient has not experienced any new infectious
episodes. Only three mild adverse reactions were reported following 98 doses. This case demonstrates the clinical utility and
safety of interferon gamma in individuals with chronic granulomatous disease. Patients who, for various reasons, are unable to
access definitive bone marrow transplantation may receive it in combination with standard antimicrobial prophylaxis.
Downloads
References
Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL,
Holland SM, et al. Human inborn errors of immunity: 2022 Update on the
Classification from the International Union of Immunological Societies
Expert Committee. J Clin Immunol [Internet]. 2022;42(7):1473-1507.
Disponible en: https://doi.org/10.1007/s10875-022-01289-3
Rider NL, Jameson MB, Creech CB. Chronic granulomatous disease:
Epidemiology, Pathophysiology, and Genetic Basis of Disease. J
Pediatric Infect Dis Soc [Internet]. 2018;7(S1):S2-5. Disponible en:
https://doi.org/10.1093/jpids/piy008
Justiz-Vaillant AA, Williams-Persad AF-A, Arozarena-Fundora R,
Gopaul D, Soodeen S, Asin-Milan O, et al. Chronic granulomatous
disease (CGD): commonly associated pathogens, diagnosis and
treatment. Microorganisms [Internet]. 2023;11(9):2233. Disponible
en: https://doi.org/10.3390/microorganisms11092233
Yu HH, Yang YH, Chiang BL. Chronic granulomatous disease:
a comprehensive review. Clin Rev Allergy Immunol [Internet].
;61(2):101-13. Disponible en: https://doi.org/10.1007/s12016-
-08800-x
López-Hernández I, Suárez-Gutiérrez M, Santos-Chávez EE, Espinosa S,
Blancas-Galicia L. Enfermedad granulomatosa crónica. Actualización
y revisión. Rev Alerg Mex [Internet]. 2019;66(2):232–45. Disponible
en: https://doi.org/10.29262/ram.v66i2.577
De Oliveira-Junior EB, Zurro NB, Prando C, Cabral-Marques O, Pereira
PVS, Schimke LF, et al. Clinical and genotypic spectrum of chronic
granulomatous disease in 71 Latin American patients: First report from
the LASID Registry. Pediatr Blood Cancer [Internet]. 2015;62(12):2101-
Disponible en: https://doi.org/10.1002/pbc.25674
Tambucci R, Angelino G, De Angelis P, Torroni F, Caldaro T, Balassone
V, et al. Anastomotic strictures after esophageal atresia repair:
incidence, investigations, and management, including treatment
of refractory and recurrent strictures. Front Pediatr [Internet].
;5:120. https://doi.org/10.3389/fped.2017.00120
Baehner RL, Nathan DG. Quantitative nitroblue tetrazolium
test in chronic granulomatous disease. N Engl J Med [Internet].
;278(18):971–6. Disponible en: https://doi.org/10.1056/
NEJM196805022781801
Roos D, de Boer M. Molecular diagnosis of chronic granulomatous
disease. Clin Exp Immunol [Internet]. 2014;175(2):139-49. Disponible
en: https://doi.org/10.1111/cei.12202
Yonkof JR, Gupta A, Fu P, Garabedián E, Dalal J. Role of allogeneic
hematopoietic stem cell transplant for chronic granulomatous disease
(CGD): a Report of the United States Immunodeficiency Network. J.
Clin. Inmunol [Internet]. 2019;39 :448–58. Disponible en: https://doi.
org/10.1007/s10875-019-00635-2
Errante PR, Frazão JB, Condino-Neto A. The use of interferon-gamma
therapy in chronic granulomatous disease. Recent Pat Antiinfect
Drug Discov [Internet]. 2008;3(3):225–30. Disponible en: https://doi.
org/10.2174/157489108786242378
Manjhi PK, Singh MP, Kumar M. Causality, severity, preventability
and predictability assessments scales for adverse drug reactions: A
Review. Cureus [Internet]. 2024;16(5):e59975. Disponible en: https://
doi.org/10.7759/cureus.59975
Weening RS, Kabel P, Pijman P, Roos D. Continuous therapy
with sulfamethoxazole-trimethoprim in patients with chronic
granulomatous disease. J Pediatr [Internet]. 1983;103(1):127-30.
Disponible en: https://doi.org/10.1016/s0022-3476(83)80798-7
Gallin JI, Buescher ES, Seligmann BE, Nath J, Gaither T, Katz P. NIH
conference. Recent advances in chronic granulomatous disease. Ann
Intern Med [Internet]. 1983;99(5):657-74. Disponible en: https://doi.
org/10.7326/0003-4819-99-5-657
Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, et al.
Itraconazole to prevent fungal infections in chronic granulomatous
disease. N Engl J Med [Internet]. 2003;348(24):2416-22. Disponible
en: https://doi.org/10.1056/NEJMoa021931
Thomas DC. The phagocyte respiratory burst: historical perspectives
and recent advances. Immunol Lett [Internet]. 2017;192:88-96.
Disponible en: https://doi.org/10.1016/j.imlet.2017.08.016
Lugo Reyes SO, González Garay A, González Bobadilla NY, Rivera
Lizárraga DA, Madrigal Paz AC, Medina-Torres EA, et al. Efficacy
and safety of interferon-gamma in chronic granulomatous disease:
a systematic review and meta-analysis. J Clin Immunol [Internet].
;43(3):578-584. Disponible en: https://doi.org/10.1007/
s10875022-01391-6
Staudacher O, von Bernuth H. Clinical presentation, diagnosis, and
treatment of chronic granulomatous disease. Front Pediatr [Internet].
;12:1384550. Disponible en: https://doi.org/10.3389/
fped.2024.1384550
Marciano BE, Wesley R, De Carlo ES, Anderson VL, Barnhart LA,
Darnell D, et al. Long-term interferon-gamma therapy for patients
with chronic granulomatous disease. Clin Infect Dis [Internet].
;39(5):692-9. Disponible en: https://doi.org/10.1086/422993
International Chronic Granulomatous Disease Cooperative Study
Group. A controlled trial of interferon gamma to prevent infection
in chronic granulomatous disease. N Engl J Med [Internet].
;324(8):509-16. Disponible en: https://doi.org/10.1056/
NEJM199102213240801
Bridges RA, Berendes H, Good RA. A fatal granulomatous disease of
childhood; the clinical, pathological, and laboratory features of a
new syndrome. AMA J Dis Child [Internet]. 1959;97(4):387-408.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 1970 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
